C57BL/6-Ppargc1atm1Aztc/Kctt

Status

Available to order

EMMA IDEM:04656
Citation informationRRID:IMSR_EM:04656 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameC57BL/6-Ppargc1atm1Aztc/Kctt
Alternative nameB6-Ppargc1a tm1Aztc
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolPpargc1atm1Aztc
Gene/Transgene symbolPpargc1a

Information from provider

ProviderMohammad Bohlooly
Provider affiliationATCG, AstraZeneca R&D
Genetic informationA straight knock out strategy, deleting exons 3 to 5, was used to target the Pgc-1alpha (Ppargc1a) locus in order to generate mice carrying knock-out alleles at this site. The targeting vector was built, using homologous recombination in bacteria BHR. A C57BL/6 mouse BAC, RP23-385G21, served as template for the extraction of homology arms of the targeting vector tab1. The targeting vector, Pgc-1alpha Delta Ex3-5, of 10.4 Kb, contained a floxed neomycin phosphotransferase, Neo, selectable marker cassette replacing sequences from intron 2 to intron 5. After linearization, the targeting construct was electroporated into AZX1, a C57BL/6J derived ES cell line.
Phenotypic informationMale heterozygous Pgc-1alpha KO mice display significantly lower body weight, body length, body lean mass and bone mineral content compared to wt littermate mice. In addition, lower food intake and higher RER, was observed in the heterozygous Pgc-1alpha KO mice. Organ weight analysis revealed significantly higher weight of the kidneys, adrenal gland and thymus and significantly lower weight of retroperitoneal adipose tissue depot in the heterozygous Pgc-1alpha KO mice. Also, heterozygous Pgc-1alpha KO mice showed lower levels of platelet count, lower total cholesterol and higher ALP levels in the blood plasma analysis. In similar, homozygous Pgc-1alpha KO female mice had lower body weight, lower body lean mass but also lower body fat mass together with lower blood glucose and insulin levels compared to wild-type littermate mice.
Breeding historyThe strain is bred on C57BL/6 in a het x wt colony. Het x het breeding is only used to produce mice for experiments.
ReferencesNone available
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreKarolinska Institutet, Stockholm, Sweden
Animals used for archivingheterozygous C57BL/6 males, wild-type C57BL/6N females
Breeding at archiving centreNo breeding.
Stage of embryos2-cell

Disease and phenotype information

IMPC phenotypes (gene matching)
  • preweaning lethality, incomplete penetrance / IMPC
MGI phenotypes (allele matching)
  • decreased body length / MGI
  • decreased body weight / MGI
  • increased circulating alkaline phosphatase level / MGI
  • thrombocytopenia / MGI
  • increased kidney weight / MGI
  • decreased lean body mass / MGI
  • increased thymus weight / MGI
  • decreased circulating cholesterol level / MGI
  • decreased retroperitoneal fat pad weight / MGI
  • decreased bone mineral content / MGI
  • decreased respiratory quotient / MGI
  • decreased food intake / MGI
  • increased adrenal gland weight / MGI
  • decreased circulating insulin level / MGI
  • decreased circulating glucose level / MGI
  • decreased body fat mass / MGI
MGI phenotypes (gene matching)
  • hypoglycemia / MGI
  • myoclonus / MGI
  • abnormal crypts of Lieberkuhn morphology / MGI
  • abnormal liver physiology / MGI
  • abnormal cerebral cortex morphology / MGI
  • abnormal hippocampus morphology / MGI
  • abnormal cerebellum morphology / MGI
  • decreased body length / MGI
  • abnormal body weight / MGI
  • decreased body weight / MGI
  • abnormal locomotor behavior / MGI
  • hyperactivity / MGI
  • increased startle reflex / MGI
  • limb grasping / MGI
  • male infertility / MGI
  • abnormal glucose homeostasis / MGI
  • abnormal lipid homeostasis / MGI
  • abnormal blood circulation / MGI
  • gliosis / MGI
  • hepatic steatosis / MGI
  • spongiform encephalopathy / MGI
  • decreased circulating insulin level / MGI
  • increased thigmotaxis / MGI
  • increased heart weight / MGI
  • decreased heart weight / MGI
  • abnormal neuron morphology / MGI
  • increased insulin sensitivity / MGI
  • fatigue / MGI
  • increased circulating alkaline phosphatase level / MGI
  • abnormal brown adipose tissue morphology / MGI
  • abnormal skeletal muscle fiber morphology / MGI
  • thrombocytopenia / MGI
  • abnormal gluconeogenesis / MGI
  • decreased cardiac output / MGI
  • muscle fatigue / MGI
  • increased tumor growth/size / MGI
  • increased kidney weight / MGI
  • decreased lean body mass / MGI
  • increased response of heart to induced stress / MGI
  • increased incidence of tumors by chemical induction / MGI
  • increased thymus weight / MGI
  • cachexia / MGI
  • decreased circulating cholesterol level / MGI
  • abnormal brainstem morphology / MGI
  • increased oxygen consumption / MGI
  • decreased oxygen consumption / MGI
  • improved glucose tolerance / MGI
  • decreased triglyceride level / MGI
  • dystonia / MGI
  • decreased heart rate / MGI
  • immune system phenotype / MGI
  • increased susceptibility to weight gain / MGI
  • increased percent body fat/body weight / MGI
  • decreased circulating glucose level / MGI
  • decreased ventricle muscle contractility / MGI
  • increased lung weight / MGI
  • decreased susceptibility to diet-induced obesity / MGI
  • abnormal basal ganglion morphology / MGI
  • congestive heart failure / MGI
  • abnormal small intestinal villus morphology / MGI
  • increased interleukin-6 secretion / MGI
  • abnormal fat cell morphology / MGI
  • decreased retroperitoneal fat pad weight / MGI
  • decreased liver triglyceride level / MGI
  • decreased gastrocnemius weight / MGI
  • decreased soleus weight / MGI
  • anhedonia / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • increased total body fat amount / MGI
  • decreased grip strength / MGI
  • decreased bone mineral content / MGI
  • decreased skeletal muscle weight / MGI
  • decreased respiratory quotient / MGI
  • abnormal cellular respiration / MGI
  • impaired adaptive thermogenesis / MGI
  • postnatal lethality, incomplete penetrance / MGI
  • decreased food intake / MGI
  • increased adrenal gland weight / MGI
  • decreased body fat mass / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).